Sign In
Buy AGEN
$3.07
+0.0300 (+0.99%)
At Close: Jun 23, 2026
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
07:30am, Tuesday, 23'rd Apr 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its f
Agenus (AGEN) Soars 6.8%: Is Further Upside Left in the Stock?
05:21am, Monday, 22'nd Apr 2024
Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
07:30am, Friday, 12'th Apr 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced updated results from its Phas
Down 75%. Is Agenus Stock a Buy on the Dip?
03:34am, Monday, 08'th Apr 2024
Shares of Agenus are way down this year, but the cancer drug developer still has some interesting assets. An experimental cancer therapy that just started phase 2 trials could generate more than $1 bi
Agenus Announces Reverse Stock Split of Common Stock
04:30pm, Friday, 05'th Apr 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced its stockholders have approve
2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now?
04:19am, Wednesday, 03'rd Apr 2024
Analyst price targets for a pair of biotech stocks suggest they can more than double your money over the next 12 months. B. Riley recently lowered expectations for Ginkgo Bioworks, but its new target
3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million
04:05pm, Sunday, 24'th Mar 2024
Here's the deal with stocks to turn $1,000 into $1 million: if you want to play, you gotta pay. I'm not just talking about the price of the securities themselves.
Agenus Inc. (AGEN) Q4 2023 Earnings Call Transcript
11:57am, Thursday, 14'th Mar 2024
Agenus Inc. (NASDAQ:AGEN) Q4 2023 Results Conference Call March 14, 2024 8:30 AM ET
Agenus Reports Fourth Quarter and Full Year 2023 Results
07:30am, Thursday, 14'th Mar 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate upd
Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
07:30am, Wednesday, 06'th Mar 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the first
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Tuesday, 05'th Mar 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compe
Why Agenus Stock Plummeted by Nearly 30% on Its Stock Split News Today
06:38pm, Thursday, 15'th Feb 2024
The clinical-stage biotech wants to push its share price well above the current minimum requirement. It is currently well under the mandated $1 per share level.
7 Analyst-Backed Stocks With Promising 10-Bagger Potential
07:09pm, Thursday, 01'st Feb 2024
Stay on the Internet long enough – and it won't take too long, believe me – and you'll come across voices that blast the virtues of analyst-backed stocks. Ranging anywhere from legitimate concerns
3 Biotech Stocks with Potential for Major Medical Breakthroughs in 2024
03:57pm, Friday, 26'th Jan 2024
After being mostly down over the past three years, the biotech sector rallied hard to end 2023. The SPDR S&P Biotech ETF (NYSEARCA: XBI ) is up 31% in the last three months.
Agenus: Taking Advantage Of The Risk-Reward Opportunity
10:22am, Wednesday, 24'th Jan 2024
Agenus Inc. has unveiled promising data from the NEST-1 study, showing the potential of the combination of botensilimab and balstilimab in colorectal cancer treatment. The combination demonstrated sig
